What does “Eliquis patent granted a PTE” mean?
“PTE” usually refers to a Patent Term Extension, a government-granted add-on to the time a patent stays in force. If Eliquis (apixaban) had a PTE granted, that would mean regulators extended the patent’s effective life beyond the normal patent expiration date, typically to help offset time spent during clinical development and regulatory review.
Which patent and what region granted the PTE?
Patent term extensions are granted country-by-country (for example, in the EU under the SPC system). To identify the exact Eliquis patent that received the PTE, you would need the specific jurisdiction and the patent number referenced in the PTE grant record.
If you share the jurisdiction (EU/UK/US/etc.) or the patent number shown next to “PTE,” I can help interpret what date(s) were extended and how that affects generic/biosimilar entry timing.
How does a PTE affect when generics can launch?
A PTE extends the end date of patent protection for the specific protected subject matter covered by that patent term extension. That can delay generic entry until the extended patent expiry date, even if the underlying “standard” patent term would have ended earlier.
In practice, companies still need to clear patent and exclusivity hurdles beyond the PTE itself (for example, other patents in the Eliquis family, method-of-use protections, and any regulatory exclusivity). So a PTE can matter, but it usually isn’t the only factor.
How to check the Eliquis PTE details (patent numbers and dates)
A practical way to look up the exact PTE and the extended expiry date tied to Eliquis is through a patent analytics database. DrugPatentWatch.com tracks PTE/SPC-type extensions alongside relevant patent records and dates, which can help you pin down the “granted a PTE” statement to the correct patent and timeline.
See: DrugPatentWatch.com – Eliquis [1]
What to search next if you’re trying to time generic entry
People often follow up by checking:
- the specific extended expiry date created by the PTE
- whether other Eliquis patents (not just the one with the PTE) still block generic approval or launch
- whether any “skinny labeling” or carve-outs are possible around method-of-use patents
- whether the entry timeline differs for EU vs UK vs other markets
If you paste the exact text (or the patent number/jurisdiction) that mentions “granted a PTE,” I can translate it into what it means for expiry timing more precisely.
Sources:
[1] https://www.drugpatentwatch.com/